Skip to main content

Advertisement

Table 2 Infection and treatment characteristics

From: Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study

  Anidulafungin Micafungin P
(n = 30) (n = 33)
Candida score at start 3 (2) 3 (3) 0.71
Source of isolatesa    0.25
 Blood 10 (33) 12 (36)  
 Intra-abdominal fluid 17 (57) 20 (63)  
 Pleural fluid 3 (10) 1 (3)  
Candida spp. a    0.46
Candida albicans 8 (27) 3 (9)  
Candida dublienis 0 (0) 2 (6)  
Candida glabrata 17 (57) 21 (66)  
Candida krusei 3 (10) 3 (10)  
Candida parapsilosis 1 (3) 2 (6)  
Candida tropicalis 1 (3) 2 (6)  
Global responsea 21 (67) 23 (70) 0.80
Clinical responsea 24 (80) 28 (85) 0.62
Microbial responsea 21 (70) 24 (73) 0.81
 Gaining negative culturesa 18 (60) 20 (60) 0.96
Duration of infection (days) 3 (5) 3 (5) 0.80
Duration of treatment (days) 12 (8) 14 (9) 0.40
Length of ICU stay (days) 13 (15) 14 (21) 0.64
Mortality day 28 after starta 20 (67) 18 (55) 0.33
Mortality day 90 after starta 26 (87) 21 (64) 0.04
  1. Numbers (percentage) aor median (interquartile range), where appropriate
  2. Abbreviations: ICU intensive care unit